Exelixis rises after cancer therapy succeeds in late-stage study

ReutersJun 23, 2025 11:00 AM

Shares of drugmaker Exelixis EXEL.O rise 23.8% to $49.97 premarket

EXEL on Sunday said its experimental oral therapy zanzalintinib, combined with Roche's ROG.S Tecentriq, improved survival in patients with a type of colorectal cancer in a late-stage study

Colorectal cancer develops in the colon’s inner lining and is the third most common cancer, according to CDC

Males are more likely to develop this type of cancer than females

As of last close, EXEL stock up 21.23% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Intel vs. TSM: Which Semiconductor Stock Looks Like the Better Investment?

TradingKey - Intel Corporation (NASDAQ: INTC) and Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) are two companies that play crucial roles in the semiconductor market; however, they each have completely different business models.

Precious Metals May Outlook: After U.S.-Iran Conflict Concerns Eased, Will Funds Flow Back to Gold and Silver?

TradingKey - Since April, the precious metals market has continued the weakness seen in March. Spot gold recorded a cumulative decline of nearly 2% in April, while spot silver briefly fell below the $70 mark.

Is SanDisk the Hidden Gem of the AI Boom in 2026? Discover the Potential Risks and Rewards.

TradingKey - SanDisk (SNDK) now represents not just a name for many consumers, but also an investment play on one of the fastest-growing sectors in technology – Artificial Intelligence.

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

TradingKey - On April 29 (ET), Microsoft (MSFT) released its Q3 FY2026 results after the bell. Both revenue and profit exceeded expectations, with Azure growth returning to 40% and annualized AI revenue surpassing $37 billion. Despite this, shares fell more than 3% in after-hours trading and ended t

$11.4 Billion Revenue Vs. 1.75 Trillion Valuation: Can Starlink Support SpaceX IPO?

TradingKey - On April 14, The Information disclosed a set of unpublished financial data: Starlink's satellite internet business revenue grew 50% year-over-year in 2025 to $11.4 billion, with EBITDA reaching $7.2 billion and an adjusted margin as high as 63%.

Featured Tools